We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Problems Surface in US Plan to Vaccinate for Smallpox

By Biotechdaily staff writers
Posted on 04 Feb 2003
Following an announcement by the US government that voluntary vaccinations of health care workers against smallpox would begin this month, concerns and objections are arising from many of those scheduled for inoculation.

The first phase of the vaccination program calls for up to 500,000 health care workers to be vaccinated in the coming weeks. More...
A later, second phase would include first responders such as police, firefighters, and emergency medical personnel. However, many of those scheduled to be vaccinated have refused and many health care workers are voicing concerns and questions.

One concern is the safety of the vaccine. When the vaccine was last used in the 1960s, there were two deaths and 52 life-threatening complications for every million people who were vaccinated. The vaccine employs the vaccinia virus, which is related to smallpox. There is a possibility that the virus may shed from the site of inoculation and infect others. This could be dangerous to those who are especially vulnerable, such as babies and people who have compromised immune systems. One important question raised is if a vaccinated health care worker has a bad reaction and cannot work for a number of days, who will pay for that time? Still another problem is the cost of the program. Many healthcare workers say the government is seriously underestimating the costs of the program, which also have to include training, screening out people at risk, following up on people with bad reactions, and managing the data from the program.

As a result, many of the hospitals and medical centers that had scheduled vaccinations are now reporting they are delaying any further involvement in the program until they have more information and can answer everyone's concerns.

"At this time, our highest priority is to vaccinate members of smallpox response teams in the states,” said Dr. Julie Gerberding, director of the US Centers for Disease Control and Prevention (CDA, Atlanta, GA, USA). "Several months of detailed planning and training, and the development of scientifically sound and informative educational materials have prepared us for the safe and rapid implementation of the plan to vaccinate those health care professionals who would be on the front lines in the event of a smallpox attack.”




Related Links:
US Centers for Disease Control and Prevention (CDC)

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.